Targeted protein degradation in modern pharmacology: A comprehensive review of PROTAC technology, molecular glues, and emerging therapeutic applications

Dr. Vandana Soneja[*1], Nooman Ansari[2], Ms. Mansi Negi[3], Ms. Parul Srivastava[4]

*[*1]Principal, Subramania Barathi College of Science and Technology, Approved by A.I.C.T.E. And P.C.I. (Govt. of India) Affiliated to B.T.E. (Govt. of NCT of Delhi)*
[2]Assistant Professor, Delhi College of Pharmacy-DIRD (nooman8377@gmail.com)
ORCID: 0009-0006-1021-4290
[3]H.O.D., Subramania Barathi College of Science and Technology, Approved by A.I.C.T.E. And P.C.I. (Govt. of India) Affiliated to B.T.E. (Govt. of NCT of Delhi)
[4]Associate Professor, Delhi College of Pharmacy, Approved by Govt. of NCT of Delhi, Affiliated to Guru Gobind Singh Indraprastha University, Dwarka, Delhi

DOI: 10.5281/zenodo.24362382

Abstract:
Targeted protein degradation (TPD) has emerged as an innovative therapeutic strategy in modern pharmacology, offering a fundamentally different approach to disease management by promoting the selective elimination of disease-associated proteins rather than merely inhibiting their biological activity. Conventional pharmacological agents generally depend on sustained interactions with specific protein targets to suppress their function. In contrast, targeted protein degradation utilizes endogenous cellular protein degradation pathways to remove unwanted or pathological proteins, potentially overcoming several limitations associated with traditional drug discovery. Among the major technologies developed in this field, proteolysis-targeting chimeras (PROTACs) and molecular glue degraders have attracted considerable scientific and pharmaceutical interest. PROTACs are heterobifunctional molecules designed to simultaneously bind a target protein and an E3 ubiquitin ligase, facilitating the formation of a ternary complex that promotes ubiquitination and subsequent proteasomal degradation. Molecular glues, in comparison, are generally smaller molecules that stabilize or induce interactions between proteins, including interactions between target proteins and E3 ubiquitin ligases, resulting in selective protein degradation. These technologies have expanded the possibilities of pharmacological intervention against previously difficult-to-target proteins, particularly in oncology, inflammatory disorders, neurological diseases, and other conditions involving abnormal protein expression or function. This review examines the molecular foundations of targeted protein degradation, structural and chemical principles underlying PROTAC development, mechanisms of molecular glue activity, and emerging approaches for improving degrader selectivity and therapeutic performance. Furthermore, it discusses pharmacokinetic and pharmacodynamic considerations, formulation and drug delivery challenges, safety concerns, and the evolving clinical development landscape. Despite significant progress, limitations involving molecular size, cellular permeability, E3 ligase availability, resistance mechanisms, and tissue-specific delivery remain important barriers to clinical translation. Continued advances in medicinal chemistry, structural biology, computational drug design, and precision medicine may facilitate the development of safer and more effective protein degradation therapeutics. Overall, targeted protein degradation represents a promising advancement in pharmaceutical research, potentially transforming conventional drug discovery into a more selective, event-driven therapeutic approach.

Keywords:
Targeted Protein Degradation, PROTACs, Molecular Glue Degraders, Ubiquitin–Proteasome System, E3 Ubiquitin Ligases, Pharmacology, Drug Discovery, Precision Medicine, Protein Degradation, Targeted Therapeutics.

1. Introduction:

The development of effective pharmacological therapies has traditionally focused on regulating the biological activity of disease-associated proteins through receptor antagonism, enzyme inhibition, competitive binding, and modulation of intracellular signaling pathways. Although these approaches have contributed significantly to the treatment of numerous diseases, conventional drug discovery continues to face substantial limitations when dealing with proteins that lack suitable binding pockets, proteins involved in complex signaling networks, and disease-associated proteins that perform multiple biological functions. In several pathological conditions, simply inhibiting one functional region of a protein may not completely prevent its disease-promoting activities. These limitations have encouraged researchers to investigate alternative therapeutic approaches capable of eliminating pathological proteins from cells rather than temporarily suppressing their activity.

Targeted protein degradation (TPD) represents an emerging pharmacological approach that utilizes endogenous cellular degradation machinery to selectively remove proteins associated with disease development and progression. Unlike conventional inhibitors, which generally require sustained target occupancy to maintain their pharmacological effects, targeted degraders can initiate the destruction of target proteins through a catalytic or event-driven mechanism. This distinction has created new opportunities for addressing proteins that were previously considered difficult or undruggable therapeutic targets (Békés et al., 2022).

The biological foundation of targeted protein degradation is closely associated with the ubiquitin–proteasome system (UPS), which regulates intracellular protein quality control, cellular signaling, protein turnover, and the elimination of damaged or unnecessary proteins. The UPS involves several coordinated enzymatic processes, including ubiquitin activation, ubiquitin conjugation, and ubiquitin ligation. E3 ubiquitin ligases play a particularly important role because they determine substrate recognition and facilitate the transfer of ubiquitin molecules to specific target proteins. Once appropriately polyubiquitinated, many proteins are recognized and degraded by the 26S proteasome (Hershko and Ciechanover, 1998).

The concept of pharmacologically redirecting endogenous protein degradation machinery was initially demonstrated through the development of proteolysis-targeting chimeras. Sakamoto et al. (2001) introduced the PROTAC concept by demonstrating that bifunctional molecules could recruit an E3 ubiquitin ligase complex to a selected protein, promoting its ubiquitination and degradation. This discovery established the foundation for a new class of therapeutic molecules capable of regulating protein abundance rather than simply interfering with protein function.

PROTAC technology has subsequently evolved through improvements in target-binding ligands, E3 ligase recruiters, linker chemistry, molecular architecture, and cellular delivery strategies. Modern PROTACs generally contain three functional components: a ligand that recognizes the target protein, a ligand that recruits an E3 ubiquitin ligase, and a chemical linker connecting both ligands. This architecture enables the formation of a target–PROTAC–E3 ligase ternary complex, facilitating ubiquitination and subsequent proteasomal degradation of the target protein (Bondeson et al., 2015).

Another important development in targeted protein degradation is the discovery and rational development of molecular glue degraders. Unlike PROTACs, which contain two distinct binding elements connected by a linker, molecular glues are generally smaller molecules that stabilize protein–protein interactions that may otherwise be weak, transient, or biologically unfavorable. Certain molecular glues facilitate the interaction between an E3 ubiquitin ligase and a target protein, resulting in substrate ubiquitination and degradation. Their relatively compact molecular architecture offers potential advantages in drug-like properties and cellular permeability (Słabicki et al., 2020).

The therapeutic significance of molecular glue technology has been demonstrated through immunomodulatory drugs such as thalidomide and its derivatives, including lenalidomide and pomalidomide. These compounds interact with cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase complex, altering its substrate recognition properties and promoting the degradation of specific cellular proteins. This mechanism has contributed to the development of effective treatments for hematological malignancies and has provided important insights into molecular glue pharmacology (Krönke et al., 2014; Lu et al., 2014).

In recent years, targeted protein degradation has attracted increasing attention in oncology because several cancer-associated proteins contribute to uncontrolled cellular proliferation, resistance to treatment, and abnormal signaling. PROTAC-based approaches targeting androgen receptors, estrogen receptors, bromodomain-containing proteins, and other oncogenic regulators have demonstrated considerable potential in preclinical and clinical investigations. The development of ARV-110 and ARV-471, for example, has illustrated the growing clinical interest in degrading androgen and estrogen receptors in hormone-dependent cancers.

Beyond oncology, targeted protein degradation is being investigated for its potential applications in inflammatory diseases, neurodegenerative disorders, viral infections, and other pathological conditions. Emerging technologies involving lysosomal degradation and autophagy-related pathways have further expanded the therapeutic scope of protein degradation beyond conventional intracellular proteasomal targets (Zhong et al., 2024).

Despite its considerable potential, several scientific and pharmaceutical challenges remain. These include the identification of suitable E3 ubiquitin ligases, optimization of ternary complex formation, molecular selectivity, metabolic stability, cellular permeability, tissue distribution, and the possibility of resistance development. Furthermore, the translation of promising preclinical findings into clinically meaningful therapeutic outcomes requires careful evaluation of pharmacokinetic properties, pharmacodynamic responses, safety, and long-term effects.

The present review therefore provides a comprehensive discussion of targeted protein degradation in modern pharmacology, with particular emphasis on PROTAC technology, molecular glue degraders, their mechanisms of action, therapeutic applications, pharmaceutical development, clinical progress, limitations, and future research opportunities.

2. Biological foundation of targeted protein degradation:

2.1. Protein Homeostasis and Cellular Protein Turnover:

Protein homeostasis, commonly referred to as proteostasis, represents the coordinated regulation of protein synthesis, folding, trafficking, cellular localization, and degradation. Maintaining protein homeostasis is essential for normal cellular function because proteins continuously undergo structural modifications, functional activation, and degradation in response to physiological and pathological conditions.

Cells possess multiple mechanisms for removing damaged, misfolded, aggregated, or unnecessary proteins. These include the ubiquitin–proteasome system, lysosomal degradation, and autophagy-associated pathways. Dysfunction in these systems may contribute to abnormal protein accumulation, cellular stress, inflammation, and disease progression.

The ubiquitin–proteasome system is particularly important for the selective degradation of intracellular proteins. It regulates the abundance of numerous proteins involved in cell-cycle progression, transcriptional regulation, DNA repair, immune responses, and intracellular signaling.

Targeted protein degradation utilizes these endogenous biological mechanisms to redirect cellular degradation machinery toward selected disease-associated proteins. This approach provides a pharmacological opportunity to control protein abundance and potentially modify pathological signaling networks.

2.2. Ubiquitin–Proteasome System:

The ubiquitin–proteasome system is an essential cellular mechanism responsible for the selective recognition and degradation of many intracellular proteins. Ubiquitin is a small regulatory protein that can be covalently attached to specific substrate proteins through an enzymatic cascade.

The ubiquitination process generally involves three major classes of enzymes:

E1: Ubiquitin-activating enzymes:

E1 enzymes initiate the ubiquitination process by activating ubiquitin in an ATP-dependent reaction. Activated ubiquitin is subsequently transferred to an E2 enzyme.

E2: Ubiquitin-conjugating enzymes:

E2 enzymes receive activated ubiquitin from E1 enzymes and participate in transferring ubiquitin to target proteins in association with E3 ubiquitin ligases.

E3: Ubiquitin ligases:

E3 ligases recognize specific protein substrates and facilitate the transfer of ubiquitin molecules to them. They are important determinants of substrate specificity within the ubiquitination pathway.

Following ubiquitination, target proteins containing appropriate ubiquitin chains may be recognized by the 26S proteasome. The proteasome subsequently unfolds and degrades the protein into smaller peptide

fragments.
This biological pathway provides the principal mechanism through which conventional PROTACs and many molecular glue degraders function (Hershko and Ciechanover, 1998; Collins and Goldberg, 2017).

Role of E3 Ubiquitin Ligases:

E3 ubiquitin ligases represent essential components of targeted protein degradation because they determine which proteins undergo ubiquitination.
Several E3 ligases have been investigated for therapeutic degrader development. Important examples include:

1. Cereblon (CRBN).
2. Von Hippel–Lindau protein (VHL).
3. Inhibitor of apoptosis proteins (IAPs).
4. Mouse double minute 2 homolog (MDM2).
5. Kelch-like ECH-associated protein 1 (KEAP1).
6. DDB1–CUL4-associated E3 ligase complexes.

CRBN and VHL are among the most frequently utilized E3 ligase systems in conventional PROTAC research. Their importance is related to the availability of small-molecule ligands capable of recruiting these ligases.
The selection of an appropriate E3 ligase depends on several factors, including tissue expression, intracellular localization, biological activity, availability of suitable ligands, and compatibility with the target protein.
Expanding the number of pharmacologically accessible E3 ligases remains an important objective because dependence on a limited number of ligases may restrict the therapeutic applicability of targeted protein degradation (Zengerle et al., 2015; Churcher, 2018).

3. Proteolysis-targeting chimeras (PROTACs):

3.1. Concept and Development of PROTAC Technology:

Proteolysis-targeting chimeras are bifunctional small molecules designed to induce selective degradation of target proteins by bringing them into proximity with E3 ubiquitin ligases.
The development of PROTAC technology represents an important transition from conventional occupancy-driven pharmacology toward event-driven pharmacology. Traditional inhibitors generally require continuous binding to their targets to suppress biological activity. In contrast, PROTACs promote the recruitment of endogenous degradation machinery, allowing target proteins to undergo ubiquitination and subsequent destruction.
Sakamoto et al. (2001) first demonstrated the feasibility of using bifunctional molecules to recruit target proteins to E3 ubiquitin ligase complexes. Subsequent research significantly improved the chemical properties and biological activity of these compounds.
The first generations of PROTACs relied on peptide-based ligands, which presented challenges involving cellular permeability, stability, and pharmaceutical development. The introduction of small-molecule ligands for E3 ligases facilitated the development of more practical and biologically active degraders.
Bondeson et al. (2015) demonstrated that small-molecule PROTACs could effectively induce degradation of selected intracellular proteins, providing important evidence supporting their development as therapeutic agents.

3.2. Structural Components of PROTACs:

A conventional PROTAC molecule consists of three principal structural components.

Target Protein-Binding Ligand:

The target-binding ligand is responsible for recognizing and binding the protein selected for degradation.
This ligand may be derived from an existing inhibitor or another small molecule capable of binding a specific protein.
The ligand does not necessarily need to inhibit the biological activity of its target. Its principal function is to facilitate the recruitment of the target protein into the degradation complex.
Target-binding ligands have been developed against several pharmacologically important proteins, including:

- Androgen receptor.
- Estrogen receptor.
- Bromodomain-containing protein 4 (BRD4).
- Bruton's tyrosine kinase (BTK).
- Cyclin-dependent kinases.
- Epidermal growth factor receptor-associated targets.

E3 Ligase-Binding Ligand:

The E3 ligase-binding ligand recruits the cellular ubiquitination machinery.

Commonly utilized E3 ligase recruiters include ligands targeting cereblon and VHL.

The choice of E3 ligase recruiter can influence degradation efficiency, selectivity, tissue distribution, and potential toxicity.

A suitable E3 ligase recruiter should demonstrate sufficient binding affinity, chemical stability, and compatibility with ternary complex formation.

Chemical Linker:

The linker connects the target-binding ligand with the E3 ligase-binding ligand.

Linker characteristics can significantly influence the biological activity of PROTAC molecules.

Important linker properties include:

- Chemical length.
- Flexibility.
- Rigidity.
- Polarity.
- Solubility.
- Conformational stability.
- Metabolic susceptibility.

A poorly optimized linker may prevent effective ternary complex formation even when both binding ligands demonstrate adequate affinity.

Therefore, linker optimization represents one of the most important stages in PROTAC development.

Mechanism of Action of PROTACs:

The mechanism of PROTAC-mediated protein degradation involves a sequence of coordinated molecular events.

Step 1: Target protein recognition:

The target-binding component of the PROTAC interacts with the selected protein.

Step 2: E3 ligase recruitment:

The second ligand binds an appropriate E3 ubiquitin ligase.

Step 3: Ternary complex formation:

The PROTAC simultaneously connects the target protein and E3 ligase, forming a ternary complex.

Step 4: Target ubiquitination:

The recruited E3 ligase facilitates ubiquitin transfer to the target protein.

Step 5: Proteasomal recognition:

The ubiquitinated protein is recognized by the cellular proteasome.

Step 6: Target protein degradation:

The target protein is unfolded and degraded into smaller peptides.

Step 7: PROTAC recycling:

Following successful degradation, the PROTAC may dissociate and participate in additional degradation cycles.

This catalytic characteristic distinguishes PROTACs from conventional inhibitors, although the extent of catalytic turnover depends on molecular properties, cellular conditions, and degradation kinetics.

Ternary Complex Formation and Cooperativity:

Ternary complex formation represents a critical determinant of PROTAC activity.

The interaction between the target protein, PROTAC molecule, and E3 ligase is influenced by several structural and thermodynamic factors.

Positive cooperativity occurs when binding of the PROTAC to one protein enhances its interaction with the other protein. Negative cooperativity occurs when the initial interaction reduces the affinity of the second binding event.

The geometry and stability of the ternary complex determine whether the target protein can be efficiently ubiquitinated.

Gadd et al. (2017) demonstrated the importance of cooperativity and ternary complex formation in PROTAC-mediated protein degradation.

These findings suggest that high-affinity binding alone does not guarantee effective degradation. The spatial arrangement of the target protein and E3 ligase is equally important.

Pharmacological Advantages of PROTACs:

PROTACs offer several potential advantages compared with conventional inhibitors.
Elimination of target proteins: PROTACs can reduce the overall abundance of disease-associated proteins rather than simply blocking their active sites.
Potential activity against difficult targets: They may facilitate therapeutic intervention against proteins lacking conventional drug-binding pockets.
Catalytic mechanism: A single PROTAC molecule may participate in multiple degradation events.
Multiple functional domains: Degradation may eliminate both enzymatic and non-enzymatic functions of a target protein.
Potential to overcome resistance: Some resistance mechanisms associated with conventional inhibitors may be addressed through protein degradation.
However, these advantages remain dependent on successful target engagement, E3 ligase recruitment, intracellular exposure, and functional degradation.

4. Molecular glue degraders:

4.1. Introduction to Molecular Glue Technology:
Molecular glue degraders represent another important category of targeted protein degradation technologies.
Unlike PROTACs, molecular glues are generally monovalent small molecules that induce or stabilize protein–protein interactions.
They facilitate the association of proteins that may not normally interact strongly under physiological conditions.
In targeted protein degradation, molecular glues can alter the substrate recognition properties of E3 ubiquitin ligases, enabling them to recognize and ubiquitinate selected target proteins.
The resulting ubiquitination can lead to proteasomal degradation.
Molecular glue degraders are particularly interesting because their relatively small molecular structures may offer favorable drug-like properties compared with larger bifunctional PROTAC molecules.
Słabicki et al. (2020) demonstrated the importance of molecular glue-induced interactions in the development of targeted protein degradation approaches.

4.2. Mechanism of Molecular Glue-Mediated Degradation:
Molecular glue-mediated degradation generally involves the following processes:
1. The molecular glue binds to a specific protein or protein complex.
2. The compound promotes or stabilizes a new protein–protein interaction.
3. An E3 ubiquitin ligase recognizes the recruited target protein.
4. The target protein undergoes ubiquitination.
5. The ubiquitinated protein is recognized by the proteasome.
6. The target protein is subsequently degraded.

Unlike conventional PROTACs, molecular glues do not necessarily require two independently identifiable ligand-binding regions connected by a chemical linker.
The molecular glue instead modifies the interaction landscape between proteins.

4.3. Immunomodulatory Drugs as Molecular Glue Degraders:
Thalidomide and its derivatives have played an important role in establishing the pharmacological significance of molecular glue degraders.
Lenalidomide and pomalidomide interact with cereblon, which functions as a substrate receptor within the CRL4 E3 ubiquitin ligase complex.
These compounds modify cereblon's substrate recognition properties, promoting the degradation of selected transcription factors and other cellular proteins.
Krönke et al. (2014) demonstrated that lenalidomide induces the degradation of IKZF1 and IKZF3, which are important transcriptional regulators in multiple myeloma.
Similarly, Lu et al. (2014) demonstrated that immunomodulatory drugs promote cereblon-dependent degradation of specific transcription factors.
These findings provided strong evidence that small molecules can redirect endogenous protein degradation machinery toward selected pathological proteins.

4.4. Molecular Glue Discovery and Design:

The discovery of molecular glue degraders has traditionally relied heavily on phenotypic screening, biological observations, and mechanistic investigations.
Modern approaches increasingly incorporate computational chemistry, structural biology, proteomics, and high-throughput screening.
Important considerations include:

- Identification of suitable protein–protein interaction interfaces.
- Recognition of E3 ligase substrate specificity.
- Molecular binding affinity.
- Protein surface complementarity.
- Cellular permeability.
- Selectivity of degradation.
- Biological consequences of target removal.

The development of systematic molecular glue discovery platforms remains an important area of pharmaceutical research.

5. Comparison between protacs and molecular glue degraders:
Although PROTACs and molecular glues share the objective of promoting selective protein degradation, their structural characteristics and mechanisms differ.

Parameter	PROTACs	Molecular Glues
Molecular architecture	Bifunctional molecules	Generally monovalent molecules
Binding components	Target ligand and E3 ligase ligand	Single molecular scaffold
Linker	Required in conventional PROTACs	Not required
Mechanism	Induces target–E3 ligase proximity	Stabilizes or induces protein–protein interactions
Molecular size	Generally larger	Generally smaller
Design approach	Modular medicinal chemistry	Often dependent on interaction discovery and optimization
Drug-like properties	Permeability and solubility can be challenging	May offer more favorable physicochemical properties
Target selection	Requires suitable target and E3 ligase ligands	Depends on compatible protein interaction interfaces
Therapeutic applications	Oncology and other disease areas	Oncology, immunology, and other emerging indications

Both approaches offer opportunities for eliminating proteins that cannot be adequately controlled using conventional pharmacological inhibition.
However, their development requires different chemical and biological optimization strategies.

6. Emerging approaches in targeted protein degradation:
Although PROTACs and molecular glues represent the most extensively investigated approaches, additional technologies are expanding the therapeutic landscape of protein degradation.

6.1. Lysosome-Targeting Chimeras (LYTACs):
LYTACs are designed to promote the degradation of extracellular and cell-surface proteins through lysosomal pathways.
Unlike conventional PROTACs, which primarily utilize the intracellular ubiquitin–proteasome system, LYTACs recruit cellular trafficking receptors to facilitate internalization and lysosomal degradation of target proteins.
Banik et al. (2020) demonstrated the feasibility of using lysosome-targeting chimeras to degrade extracellular proteins and membrane-associated targets.
This approach may provide opportunities for targeting proteins that are inaccessible to conventional intracellular degraders.

6.2. Autophagy-Targeting Chimeras (AUTACs):

AUTACs represent another emerging approach designed to promote the degradation of selected cellular components through autophagy-related pathways.

Autophagy is an intracellular process through which cells deliver proteins, organelles, and other cellular materials to lysosomes for degradation.

AUTAC technology has been investigated for its potential to eliminate specific proteins and damaged cellular components.

These strategies may offer therapeutic opportunities in diseases associated with abnormal protein accumulation and impaired cellular quality control.

6.3. Autophagosome-Tethering Compounds (ATTECs):

ATTECs facilitate the interaction between target proteins and LC3, a protein associated with autophagosome formation.

This interaction can promote the sequestration of selected target proteins into autophagosomes, followed by lysosomal degradation.

Li et al. (2019) demonstrated the potential of autophagosome-tethering compounds for targeting disease-associated proteins.

Such approaches are particularly interesting in neurodegenerative disorders involving abnormal protein aggregation.

6.4. Hydrophobic Tagging:

Hydrophobic tagging is a protein degradation strategy that uses hydrophobic chemical groups to promote the recognition of target proteins by cellular protein quality-control mechanisms.

The introduction of hydrophobic tags can destabilize target proteins or facilitate their recognition by cellular degradation machinery.

This approach provides an alternative method for inducing protein degradation without necessarily recruiting a conventional E3 ligase through a bifunctional molecule.

6.5. Antibody-Based Protein Degradation Technologies:

Antibody-based degradation strategies are being explored to improve the targeting of extracellular and membrane-associated proteins.

These technologies may combine antibody recognition with cellular internalization and lysosomal degradation mechanisms.

Their development could expand the range of proteins accessible to targeted degradation beyond intracellular targets.

7. Therapeutic applications of targeted protein degradation:

7.1. Oncology and Cancer Pharmacology:

Cancer represents one of the most extensively investigated therapeutic areas for targeted protein degradation.

Cancer progression frequently involves abnormal expression, mutation, amplification, or activation of proteins responsible for cell proliferation, survival, angiogenesis, and resistance to treatment.

Conventional inhibitors may provide effective suppression of specific signaling pathways; however, incomplete inhibition, compensatory mechanisms, and acquired resistance can limit their long-term effectiveness.

Targeted protein degradation offers an alternative strategy by removing disease-associated proteins from cancer cells.

7.2. Androgen Receptor Degradation:

The androgen receptor plays an important role in the development and progression of prostate cancer.

Although androgen receptor antagonists and androgen synthesis inhibitors have improved the management of prostate cancer, treatment resistance remains an important clinical challenge.

PROTAC-based androgen receptor degraders are being investigated to eliminate androgen receptor proteins and suppress androgen-dependent signaling.

ARV-110, also known as bavdegalutamide, is an investigational androgen receptor degrader developed for prostate cancer.

Its development illustrates the potential of targeted protein degradation in hormone-dependent malignancies.

7.3. Estrogen Receptor Degradation:

Estrogen receptor signaling contributes significantly to the development and progression of hormone receptor-positive breast cancer.
Selective estrogen receptor degraders and other endocrine therapies have improved treatment outcomes. However, acquired resistance and altered receptor signaling continue to create therapeutic challenges.
PROTAC-based estrogen receptor degraders are being developed to promote receptor elimination.
ARV-471, also known as vepdegestrant, is an investigational estrogen receptor degrader that has attracted considerable clinical interest.
The development of estrogen receptor-targeting PROTACs represents an important example of translating protein degradation technology into oncology.

7.4. BRD4 and BET Protein Degradation:

Bromodomain-containing protein 4 is involved in transcriptional regulation and the expression of genes associated with cellular proliferation and cancer development.
BET proteins have been investigated as therapeutic targets in several malignancies.
PROTAC-based degradation of BRD4 offers an approach for suppressing its biological functions through protein elimination.
This strategy may provide advantages in situations where conventional bromodomain inhibitors produce incomplete suppression of disease-associated transcriptional activity.

7.5. Targeting Mutant Oncoproteins:

Several oncogenic proteins have historically been difficult to target using conventional small-molecule inhibitors.
Targeted degradation may provide opportunities to remove selected mutant or abnormal proteins involved in cancer development.
Research involving RAS-associated proteins, transcriptional regulators, and other oncogenic targets has expanded the potential applications of TPD in cancer pharmacology.
However, effective degradation of these proteins depends on the availability of suitable binding ligands, appropriate E3 ligases, and favorable intracellular conditions.

7.6. Neurodegenerative Disorders:

Neurodegenerative disorders are frequently associated with abnormal protein accumulation, aggregation, impaired proteostasis, and progressive neuronal dysfunction.
Examples include:

- Alzheimer's disease.
- Parkinson's disease.
- Huntington's disease.
- Amyotrophic lateral sclerosis.

Targeted protein degradation has attracted interest because several proteins involved in these disorders may contribute to neuronal damage through abnormal accumulation or pathological interactions.

7.7. Alzheimer's Disease:

Alzheimer's disease is associated with abnormal accumulation of amyloid-beta peptides and tau protein pathology.
These pathological processes contribute to neuronal dysfunction and progressive cognitive impairment.
Protein degradation approaches are being explored to reduce selected disease-associated proteins.
However, the development of effective degraders for neurological conditions requires consideration of blood–brain barrier penetration, neuronal uptake, tissue distribution, and long-term safety.

7.8. Parkinson's Disease:

Parkinson's disease involves progressive degeneration of dopaminergic neurons and is associated with abnormal alpha-synuclein accumulation in several disease forms.
Autophagy-based and other targeted degradation strategies may provide opportunities to reduce pathological protein accumulation.
ATTEC-based approaches and other emerging degradation technologies have generated interest in this area.
Nevertheless, their therapeutic efficacy and safety require further investigation.

7.9. Huntington's Disease:

Huntington's disease is associated with abnormal expansion of CAG repeats in the huntingtin gene, resulting in the production of mutant huntingtin protein.
The accumulation of mutant huntingtin contributes to neuronal dysfunction and neurodegeneration.
Targeted protein degradation may offer a potential strategy for reducing mutant huntingtin protein levels.
Further research is required to establish effective delivery systems and minimize unwanted effects on normal huntingtin function.

7.10. Inflammatory and Autoimmune Disorders:

Inflammatory and autoimmune diseases involve abnormal regulation of immune signaling pathways, cytokine production, and intracellular transcriptional networks.
Several proteins involved in these pathways have been investigated as potential targets for degradation.
Targeted degradation of selected inflammatory signaling proteins may provide an alternative to conventional enzyme inhibitors and receptor antagonists.
Potential therapeutic targets include proteins involved in:

- NF-κB signaling.
- Janus kinase pathways.
- Cytokine-associated signaling.
- Immune-cell activation.
- Inflammatory transcriptional regulation.

However, because many immune proteins perform essential physiological functions, selective target degradation and careful safety evaluation are particularly important.

7.11. Viral and Infectious Diseases:

Targeted protein degradation is also being investigated as a potential approach for managing infectious diseases.
Certain viral proteins are essential for viral replication, cellular entry, or immune evasion.
The selective elimination of viral proteins could potentially interfere with viral replication and disease progression.
An important advantage of this approach is that it may provide a different mechanism of action compared with conventional antiviral agents.
However, the development of effective antiviral degraders requires suitable viral protein-binding ligands, intracellular delivery, and evaluation of host-cell safety.

7.12. Cardiovascular Diseases:

Cardiovascular diseases involve multiple molecular pathways associated with inflammation, fibrosis, cellular stress, vascular remodeling, and abnormal cardiac signaling.
Targeted protein degradation may provide opportunities to regulate selected disease-associated proteins involved in these pathways.
Potential research areas include:

- Proteins involved in cardiac hypertrophy.
- Inflammatory signaling mediators.
- Fibrosis-associated proteins.
- Abnormal vascular signaling proteins.
- Proteins associated with pathological cardiac remodeling.

At present, cardiovascular applications remain an emerging research area compared with oncology. Further experimental and translational studies are necessary to establish their clinical relevance.

8. Pharmaceutical development and drug design considerations:

8.1. Rational Design of PROTAC Molecules:

The development of effective PROTACs requires coordinated optimization of molecular recognition, linker architecture, and E3 ligase recruitment.
The design process generally begins with identifying a disease-associated protein and determining whether a suitable ligand is available.
Medicinal chemists subsequently select an appropriate E3 ligase recruiter and investigate different linker

structures.

Modern PROTAC optimization may involve:

1. Target identification and validation.
2. Selection of a target-binding ligand.
3. Identification of a suitable E3 ligase.
4. Selection of an E3 ligase recruiter.
5. Linker synthesis and optimization.
6. Ternary complex evaluation.
7. Cellular degradation assessment.
8. Selectivity and toxicity studies.
9. Pharmacokinetic evaluation.
10. Preclinical therapeutic assessment.

The design process requires integration of chemical biology, computational modeling, structural biology, and pharmacological evaluation.

8.2. Structure–Activity Relationship:

Structure–activity relationship studies are essential for understanding how chemical modifications influence PROTAC activity.

Changes in the target-binding ligand, E3 ligase recruiter, and linker can significantly influence degradation potency and selectivity.

Important parameters include:

- Binding affinity.
- Degradation concentration.
- Maximum degradation response.
- Degradation kinetics.
- Ternary complex cooperativity.
- Cellular permeability.
- Solubility.
- Metabolic stability.

A compound demonstrating high binding affinity may not necessarily produce efficient degradation. Therefore, pharmacological evaluation should include direct measurement of target protein reduction rather than relying exclusively on binding assays.

8.3. Computational Drug Design:

Computational drug design has become increasingly important in the development of targeted protein degraders.

Molecular docking, molecular dynamics simulations, protein structure prediction, and artificial intelligence-assisted screening can support the identification of suitable binding interactions.

These approaches may help predict:

- Target-binding affinity.
- E3 ligase recruitment.
- Ternary complex stability.
- Linker conformational preferences.
- Molecular interactions.
- Potential degradation selectivity.

However, computational predictions require experimental validation because protein–protein interactions and degradation outcomes depend on complex cellular processes.

8.4. Analytical Characterization:

The pharmaceutical development of PROTACs and molecular glues requires appropriate analytical characterization.

Common analytical approaches include:

High-performance liquid chromatography: Used for assessing purity, related substances, and chemical stability.

Liquid chromatography–mass spectrometry: Used for molecular identification, impurity profiling, and pharmacokinetic analysis.

Nuclear magnetic resonance spectroscopy: Used for confirming chemical structure and molecular integrity.
Mass spectrometry-based proteomics: Used for identifying protein degradation profiles and evaluating selectivity.
Western blotting: Used for measuring changes in target protein expression.
Cell-based degradation assays: Used for evaluating degradation potency and concentration-response relationships.
These techniques help establish the relationship between molecular structure, chemical properties, and biological activity.

9. Pharmacokinetic and pharmacodynamic considerations:

9.1. Absorption:
The absorption of targeted protein degraders depends on their molecular structure, solubility, permeability, and formulation characteristics.
PROTAC molecules are generally larger than conventional small-molecule inhibitors because they contain multiple functional components.
This increased molecular complexity may create challenges involving oral absorption and membrane permeability.
Therefore, pharmaceutical optimization is necessary to improve absorption and systemic exposure.

9.2. Distribution:
Drug distribution determines whether a degrader reaches the tissues and cells containing its intended target protein.
Tissue-specific expression of E3 ligases and differences in cellular permeability can influence degradation responses.
For example, degraders intended for neurological disorders must overcome the blood–brain barrier to achieve sufficient exposure within the central nervous system.
Similarly, compounds targeting tumors must demonstrate appropriate tumor penetration and intracellular availability.

9.3. Metabolism:
Metabolic stability is an important determinant of the pharmacokinetic behavior of targeted degraders.
The chemical structure of PROTAC molecules may contain metabolically susceptible bonds or functional groups.
Metabolic modification can alter molecular integrity, target-binding affinity, E3 ligase recruitment, and overall degradation activity.
Preclinical metabolism studies are therefore necessary to identify metabolites and evaluate their potential pharmacological activity.

9.4. Excretion:
The elimination of targeted protein degraders depends on their physicochemical properties, metabolism, and interactions with biological transport systems.
Renal and hepatic elimination may contribute to the clearance of parent compounds and their metabolites.
Understanding elimination pathways is important for determining dosing frequency and potential drug–drug interactions.

9.5. Pharmacodynamic Assessment:
Pharmacodynamic evaluation of targeted degraders differs from conventional inhibitors because the principal therapeutic objective is a measurable reduction in target protein abundance.
Important pharmacodynamic parameters include:

- Percentage of target protein degradation.
- Degradation concentration.
- Time required to achieve maximum degradation.
- Duration of protein suppression.
- Recovery of target protein expression.
- Downstream biological responses.

Pharmacodynamic assessment should also distinguish direct target degradation from secondary changes in protein expression caused by cellular stress or altered signaling.

10. Formulation and drug delivery challenges:

The pharmaceutical formulation of targeted protein degraders represents an important area of ongoing research.

Their relatively large molecular structures, complex chemical architecture, and variable physicochemical properties may create challenges for conventional drug delivery.

10.1. Lipid-Based Drug Delivery Systems:

Lipid-based formulations may provide opportunities to improve the delivery of selected targeted degraders.

Lipid nanoparticles and other lipid-based carriers can potentially enhance cellular uptake and protect sensitive therapeutic molecules.

However, the suitability of these systems depends on the chemical nature of the degrader and its compatibility with the delivery platform.

10.2. Nanoparticle-Based Delivery:

Nanoparticle-based delivery systems may facilitate tissue-specific distribution and improve the intracellular availability of targeted degraders.

Potential advantages include:

- Improved solubility.
- Controlled drug release.
- Protection against premature degradation.
- Enhanced cellular uptake.
- Possibility of targeted tissue delivery.

However, nanoparticle formulation requires careful evaluation of particle size, surface characteristics, encapsulation efficiency, release kinetics, and biocompatibility.

10.3. Prodrug Strategies:

Prodrug development may provide an opportunity to improve the pharmacokinetic properties of selected targeted degraders.

Chemical modifications can potentially enhance solubility, membrane permeability, or tissue distribution.

After administration, the prodrug may undergo enzymatic or chemical conversion to release the active degrader.

This approach remains an interesting area for future pharmaceutical development.

10.4. Blood–Brain Barrier Penetration:

The blood–brain barrier represents a major obstacle in the development of targeted degraders for neurological disorders.

The delivery of pharmacologically active compounds into the central nervous system depends on molecular size, lipophilicity, transport mechanisms, and other physicochemical characteristics.

Developing brain-penetrant PROTACs and appropriate delivery systems may expand their therapeutic applications in neurodegenerative diseases.

11. Safety, toxicity, and resistance mechanisms:

11.1. Off-Target Protein Degradation:

Off-target degradation represents an important safety concern in targeted protein degradation.

A PROTAC may recruit unintended proteins to an E3 ligase if the molecular interactions are insufficiently selective.

Unintended protein degradation may alter essential cellular processes and produce undesirable biological effects.

Comprehensive proteomic profiling is therefore important during preclinical development.

11.2. E3 Ligase-Associated Toxicity:

The selection of an appropriate E3 ligase is important because E3 ligases participate in numerous physiological processes.

Excessive or inappropriate recruitment of degradation machinery may affect proteins involved in normal cellular regulation.
Furthermore, differences in E3 ligase expression among tissues may influence the safety profile of a degrader.

11.3. Immunological Effects:

Certain protein degraders may alter immune-related proteins or signaling pathways.
These effects may be therapeutically beneficial in some diseases but could also produce unwanted immunological consequences.
Therefore, immunotoxicity and changes in immune-cell function should be considered during drug development.

11.4. Development of Resistance:

Resistance to targeted protein degradation may occur through several mechanisms.
Potential mechanisms include:

- Reduced expression of the recruited E3 ligase.
- Mutations affecting target-binding sites.
- Altered protein localization.
- Changes in ubiquitination machinery.
- Increased target protein synthesis.
- Adaptation of cellular degradation pathways.
- Changes in proteasome activity.

In cancer, acquired resistance may reduce the effectiveness of a degrader despite initially favorable pharmacological responses.
Understanding these mechanisms is essential for developing next-generation degraders and combination treatment strategies.

12. Clinical development and translational progress:

The clinical development of targeted protein degradation has progressed substantially from early chemical biology investigations to human therapeutic studies.
The first clinical programs largely focused on oncology because several cancer-associated proteins represent suitable targets for degradation.
PROTAC-based therapies targeting androgen and estrogen receptors have attracted particular interest.
ARV-110 and ARV-471 illustrate the translation of PROTAC technology into clinical development.
Molecular glue degraders have also established clinical relevance through immunomodulatory drugs such as lenalidomide and pomalidomide.
These compounds demonstrate that small molecules can alter E3 ligase substrate recognition and induce therapeutically relevant protein degradation.
The clinical development landscape is expanding beyond conventional PROTACs and molecular glues toward alternative degradation pathways.
Current research includes:

- Intracellular proteasomal degradation.
- Lysosome-dependent degradation.
- Autophagy-mediated degradation.
- Extracellular protein degradation.
- Tissue-selective degradation.
- Degradation of membrane-associated proteins.

Tsai et al. (2024) highlighted the expanding clinical landscape of targeted protein degradation and emphasized the importance of understanding degradation mechanisms for successful therapeutic translation.
Zhong et al. (2024) also discussed the development of PROTACs, molecular glues, and emerging lysosomal degradation technologies.
Although early clinical findings have demonstrated the feasibility of targeted protein degradation, further evidence is required to establish comparative clinical efficacy, long-term safety, optimal dosing, and therapeutic positioning.

13. Combination therapy and precision pharmacology:

The combination of targeted protein degradation with other therapeutic approaches may provide opportunities

to improve treatment outcomes.
In oncology, degraders may be investigated alongside conventional chemotherapy, hormonal therapy, immunotherapy, and targeted kinase inhibitors.
Combination strategies may help suppress compensatory signaling pathways and reduce the development of resistance.
Precision pharmacology may further improve the selection of patients who are most likely to benefit from specific degradation approaches.
Important considerations include:

- Expression of the target protein.
- Availability of the relevant E3 ligase.
- Genetic alterations.
- Molecular subtype of disease.
- Previous treatment exposure.
- Potential drug–drug interactions.
- Pharmacodynamic response.

Proteomic and genomic profiling may help identify suitable therapeutic targets and predict the response to targeted degraders.
However, clinical combination strategies must be evaluated carefully to avoid additive toxicity and unwanted protein degradation.

14. Challenges and limitations:

Despite considerable scientific progress, targeted protein degradation continues to face several pharmaceutical and clinical challenges.

Limited E3 Ligase Availability:

The number of E3 ligases with well-characterized small-molecule recruiters remains limited.
Dependence on a small number of ligases may restrict target selection and tissue-specific applications.
Identifying new ligandable E3 ligases is therefore an important research priority.

Molecular Size and Permeability:

Conventional PROTACs often possess relatively large molecular structures.
These properties may negatively affect oral bioavailability, passive membrane permeability, and tissue distribution.
Improving molecular properties without compromising degradation activity remains a major medicinal chemistry challenge.

Selectivity:

Targeted degraders must demonstrate sufficient selectivity to avoid unintended protein degradation.
Off-target activity may result from unintended binding interactions or recruitment of alternative proteins into degradation complexes.
Advanced proteomic approaches are important for evaluating degradation selectivity.

Pharmacokinetic Complexity:

The pharmacokinetic behavior of PROTACs may differ from that of conventional inhibitors.
Drug exposure does not necessarily correlate directly with degradation response because the latter also depends on target abundance, E3 ligase expression, ternary complex formation, and protein resynthesis.
Consequently, conventional pharmacokinetic measurements may need to be integrated with detailed pharmacodynamic evaluation.

Clinical Translation:

Promising preclinical activity does not automatically establish clinical efficacy.
Differences between experimental models and human disease biology may affect therapeutic outcomes.
Long-term safety, optimal patient selection, dosing schedules, and treatment resistance require further investigation.

15. Future perspectives:

The future of targeted protein degradation is expected to involve substantial advances in medicinal chemistry, molecular biology, computational drug design, and pharmaceutical formulation.
One important direction is the development of selective degraders capable of targeting proteins previously considered pharmacologically inaccessible.
The expansion of E3 ligase recruiters may improve tissue selectivity and increase the range of proteins that

can be targeted.
Artificial intelligence and machine learning may support the identification of suitable binding ligands, prediction of ternary complex structures, and optimization of linker architecture.
Structural biology and cryo-electron microscopy may provide additional insights into protein–protein interactions and degradation mechanisms.
Another important research direction involves improving the delivery of degraders to specific tissues.
Nanotechnology-based delivery, prodrug strategies, and targeted formulation approaches may help overcome limitations associated with molecular size and poor permeability.
The development of brain-penetrant degraders may be particularly important for neurodegenerative disorders.
Molecular glue discovery is also expected to benefit from advances in high-throughput screening and computational approaches.
These developments may facilitate the identification of novel compounds capable of inducing selective protein–protein interactions.
Furthermore, the integration of proteomics, genomics, and precision medicine may help identify patient populations most likely to respond to specific degraders.
However, future development should emphasize not only degradation potency but also selectivity, safety, pharmacokinetic behavior, and clinically meaningful outcomes.

16. Conclusion:

Targeted protein degradation represents an important advancement in modern pharmacology because it provides an alternative approach to conventional protein inhibition by promoting the selective elimination of disease-associated proteins. PROTACs and molecular glue degraders have emerged as two major technologies within this field, offering different molecular strategies for redirecting endogenous cellular degradation machinery toward selected therapeutic targets.
PROTACs utilize bifunctional molecular structures containing a target-binding ligand, an E3 ligase recruiter, and a connecting linker. Their ability to promote ternary complex formation and subsequent ubiquitination provides opportunities to eliminate proteins involved in disease progression. Molecular glues, in contrast, promote or stabilize protein–protein interactions that facilitate selective substrate recognition and degradation.
The therapeutic applications of these technologies are expanding across oncology, inflammatory disorders, neurodegenerative diseases, and other emerging research areas. Their clinical development has demonstrated the feasibility of translating targeted protein degradation into therapeutic strategies, particularly in hormone-dependent cancers and hematological malignancies.
Nevertheless, challenges involving molecular permeability, E3 ligase availability, degradation selectivity, pharmacokinetics, resistance, and long-term safety remain important barriers to widespread clinical application.
Future advances in medicinal chemistry, computational drug discovery, proteomics, nanotechnology, and precision medicine may help overcome these limitations. Overall, targeted protein degradation has the potential to transform pharmaceutical research by shifting therapeutic strategies from the inhibition of pathological proteins toward their selective and controlled elimination.

17. References:

(1) Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001;98(15):8554-9. doi:10.1073/pnas.141230798.
(2) Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-79. doi:10.1146/annurev.biochem.67.1.425.
(3) Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611-7. doi:10.1038/nchembio.1858.
(4) Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol. 2015;10(8):1770-7. doi:10.1021/acschembio.5b00216.
(5) Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J Med Chem. 2018;61(2):444-52. doi:10.1021/acs.jmedchem.7b01272.
(6) Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017;13(5):514-21. doi:10.1038/nchembio.2329.
(7) Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell. 2017;169(5):792-806.

doi:10.1016/j.cell.2017.04.023.

(8) Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-5. doi:10.1126/science.1244851.

(9) Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305-9. doi:10.1126/science.1244917.

(10) Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020;585(7824):293-7. doi:10.1038/s41586-020-2374-x.

(11) Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181-200. doi:10.1038/s41573-021-00371-6.

(12) Crews CM. Targeting the undruggable proteome: the small molecules of my dreams. Chem Biol. 2010;17(6):551-5. doi:10.1016/j.chembiol.2010.05.012.

(13) Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376-81. doi:10.1126/science.aab1433.

(14) Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs)—past, present and future. Drug Discov Today Technol. 2019;31:15-27. doi:10.1016/j.ddtec.2019.01.002.

(15) Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101-14. doi:10.1038/nrd.2016.211.

(16) Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584(7820):291-7. doi:10.1038/s41586-020-2545-9.

(17) Li Z, Wang C, Wang Z, Zhu C, Li J, Sha T, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019;575(7781):203-9. doi:10.1038/s41586-019-1722-1.

(18) Tsai JM, Nowak RP, Ebert BL, Fischer ES. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol. 2024;25(9):740-57. doi:10.1038/s41580-024-00729-9.

(19) Zhong G, Chang X, Xie W, Zhou X, et al. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308. doi:10.1038/s41392-024-02004-x.

(20) Pan Y, Wang Y, Gou S. Proteolysis targeting chimera, molecular glue degrader and hydrophobic tag tethering degrader for targeted protein degradation: mechanisms, strategies and application. Bioorg Chem. 2025;161:108491. doi:10.1016/j.bioorg.2025.108491.

(21) Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE, et al. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025;25:493-516. doi:10.1038/s41568-025-00817-8.

(22) Mohammed AS, Nadeem, Kumar M, Singh B, Chawla A. Role of herbal medicines in the treatment of depression: a comprehensive review. Scienxt J Pharm Sci. 2026;4(2): July–December. doi:10.5281/zenodo.22869446.

(23) Kumar HS, Venkatachalapathy M, Sistla R, Poongavanam V. Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation. Drug Discov Today. 2024;29(11):104205. doi:10.1016/j.drudis.2024.104205.

(24) Osman J, Thompson PE, Jörg M, Scanlon MJ. Methods to accelerate PROTAC drug discovery. Biochem J. 2025;482:921-37. doi:10.1042/BCJ20243018.

(25) Fu MJ, et al. Unleashing the power of covalent drugs for protein degradation. Med Res Rev. 2025. doi:10.1002/med.22101.

(26) Kim S, Jeung EB. Targeted protein degradation: therapeutic potential and challenges of PROTACs and molecular glues. J Biomed Transl Res. 2025;26(2):21-34. doi:10.12729/jbtr.2025.26.2.21.